Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025)
PHASE1CompletedINTERVENTIONAL
Enrollment
38
Participants
Timeline
Start Date
February 28, 2014
Primary Completion Date
July 9, 2015
Study Completion Date
March 31, 2017
Conditions
Non-small Cell Lung Cancer
Interventions
BIOLOGICAL
Pembrolizumab
Intravenous infusion
All Listed Sponsors
lead
Merck Sharp & Dohme LLC
INDUSTRY
NCT02007070 - Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025) | Biotech Hunter | Biotech Hunter